Q-omics provides the consensus-scored TMEM271 profile across patient tissues and cancer cell-line models. TMEM271 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM271 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, TMEM271 RNA expression shows 11,048 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where TMEM271 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM271 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM271 survival associations across molecular data types. TMEM271 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM271 RNA expression–survival associations across cancer types. High TMEM271 expression shows unfavorable associations in KIRC, KICH, MESO and ACC, but favorable associations in HNSC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM271 RNA expression.
This table summarizes TMEM271 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM271. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM271 shows lower tumor expression in COAD, HNSC, READ, STAD and BRCA and higher tumor expression in LUSC. The COAD box plot shows higher TMEM271 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with TMEM271 in patient tissues and cancer cell lines. In patient samples, TMEM271 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
